SETD4 and cancer: Specifically, SETD4 correlated positively with immune checkpoint inhibitors in some cancer types, including BLCA, CESC, PAAD, SARC, and UVM, but negatively in ACC, COAD, KICH, LIHC, Ovarian Serous Cystadenocarcinoma (OV), READ, STAD, THCA, and UCEC (Figure 6C).